The Potential Role of GnRH Agonists and Antagonists in Inducing Thyroid Physiopathological Changes During IVF

Abstract

We conducted an observational cohort study to evaluate whether drugs used for hypothalamic inhibition may impact thyroid function of infertile women scheduled for fresh nondonor in vitro fertilization/intracytoplasmic sperm injection treatment. We considered eligible for inclusion in the study only women with normal thyroid function (serum thyroid-stimulating hormone [TSH] range: 0.2-4.0 mIU/L, serum thyroxin values: 9-22 pmol/L) and negative personal history for previous thyroid disorders. According to which protocols were implemented to gain hypothalamic inhibition, patients were assigned to group A (70 women treated by long gonadotropin-releasing hormone [GnRH] agonist protocol) or to group B (86 women treated by flexible GnRH antagonist protocol). Before initiating controlled ovarian stimulation (COS), both groups were further stratified into 4 subgroups: A1 (46 of the 70 women) and B1 (61 of the 86 women) in women with a baseline TSH value <2.5 mIU/L, whereas those with a baseline value ≥2.5 mIU/L were assigned to groups A2 (24 of the 70 women) and B2 (25 of the 86 women). Prior to initiating stimulation (T-0), 17-β-estradiol (E₂) and TSH serum values were dosed in all women and repeated on T-5 (day 5 of COS) and subsequently every 2 days until T-ov-ind (ovulation induction day) and T-pick-up (oocytes retrieval day). In case of detection of TSH levels above the cutoff, patients were screened for thyroxin and thyroid autoantibody serum values. In group A, E₂ at T-ov-ind was significantly increased compared to group B (P < .01), whereas TSH values showed an opposite trend (not significantly modified in group A, whereas significantly increased in group B; P < .001). A total of 64 women were found to have TSH values above the cutoff during COS: 7 in group A (11%) and 57 in group B (89%). Among them, 5 (71.4%) of the 7 in group A displayed hypothyroidism (and 4 of the 5 autoantibody positivity), whereas in group B, 6 (10.5%) of the 57 displayed hypothyroidism (and 2 of the 6 autoantibody positivity; P < .001). No pregnancies were observed in women with hypothyroidism, whereas in the 53 women with “isolated” increased TSH (normal T4, negative antibodies), we reported a 20.7% clinical pregnancy rate and a 54.5% ongoing pregnancy rate. Our preliminary data, despite requiring further confirmation, seem to suggest that the various drugs used for gaining hypothalamic control during COS could interfere through different mechanisms with physiological function of thyroid axis, potentially affecting its regulation.

Keywords

GnRH antagonist controlled ovarian stimulation thyroid function thyroid-stimulating hormone thyroid autoimmunity pregnancy rate IVF outcome

Get full access to this article

View all access options for this article.

References

Gizzo

Andrisani

Esposito

. Ovarian reserve test: an impartial means to resolve the mismatch between chronological and biological age in the assessment of female reproductive chances. Reprod Sci. 2014;21(5):632–639.

Vitagliano

Quaranta

Noventa

Gizzo

. “Empiric” inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet. 2015;291(5):955–957.

Gizzo

Capuzzo

Zicchina

. Could empirical low-dose-aspirin administration during IVF cycle affect both the oocytes and embryos quality via COX 1-2 activity inhibition? J Assist Reprod Genet. 2014;31(3):261–268.

Vitagliano

Noventa

Gizzo

. Emerging evidence regarding statins use as novel endometriosis targeted treatment: real “magic pills” or “trendy” drugs? Some considerations. Eur J Obstet Gynecol Reprod Biol. 2015;184:125–126.

Mintziori

Goulis

Toulis

Venetis

Kolibianakis

Tarlatzis

. Thyroid function during ovarian stimulation: a systematic review. Fertil Steril. 2011;96(3):780–785.

Benaglia

Busnelli

Somigliana

. Incidence of elevation of serumthyroid-stimulatinghormoneduringcontrolledovarianhyperstimulation for in vitro fertilization. Eur J Obstet Gynecol Reprod Biol. 2014;173:53–57.

La Rosa

Celato

Uccella

Capella

. Detection of gonadotropin-releasing hormone receptor in normal human pituitary cells and pituitary adenomas using immunohistochemistry. Virchows Arch. 2000;437(3):264–269.

Hong

Klausen

Cheung

Leung

. Gonadotropin-releasing hormone-I or -II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrinol Metab. 2012;97(2):525–534.

Tan

Carr

Beshay

Bukulmez

. The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review. Reprod Sci. 2013;20(1):16–25.

10.

Han

Song

Yang

. Thyroid dysfunction associated with administration of the long-acting gonadotropin-releasing hormone agonist. Endocrinol Metab (Seoul). 2013;28(3):221–225.

11.

Rizvi

Rehm

. Recombinant human thyrotropin use resulting in ovarian hyperstimulation: an unusual side effect. Eur Thyroid J. 2014;3(2):125–129.

12.

Aghajanova

Lindeberg

Carlsson

. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue. Reprod Biomed Online. 2009;18(3):337–347.

13.

Orvieto

. GnRH agonist versus GnRH antagonist in ovarian stimulation: has the ongoing debate resolved? Reprod Biomed Online. 2014;29(5):647–649.

14.

Gizzo

Andrisani

Noventa

. Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART. Reprod Biol Endocrinol. 2015;13:28.

15.

Patrelli

Berretta

Gizzo

. CA 125 serum values in surgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate. Fertil Steril. 2011;95(1):393–396.

16.

Gizzo

Patrelli

Rossanese

. An update on diabetic women obstetrical outcomes linked to preconception and pregnancy glycemic profile: a systematic literature review. ScientificWorld J. 2013;2013:254901.

17.

Saccardi

Conte

Fabris

. Hysteroscopic enucleation in toto of submucous type 2 myomas: long-term follow-up in women affected by menorrhagia. Minim Invasive Gynecol. 2014;21(3):426–430.

18.

Litta

Cosmi

Saccardi

Esposito

Rui

Ambrosini

. Outpatient operative polypectomy using a 5 mm-hysteroscope without anaesthesia and/or analgesia: advantages and limits. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):210–214.

19.

Vitagliano

Noventa

Gizzo

. Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional D-chiro inositol supplementation? Hypothesis, rationale and some considerations. J Assist Reprod Genet. 2015;32(3):407–408.

20.

Gizzo

Andrisani

Esposito

. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial [published online September 30, 2014]. Gynecol Endocrinol. 2014:1–7.

21.

Gracia

Morse

Chan

. Thyroid function during controlled ovarian hyperstimulation as part of in vitro fertilization. Fertil Steril. 2012;97(3):585–591.

22.

Poppe

Glinoer

Tournaye

Schiettecatte

Haentjens

Velkeniers

. Thyroid function after assisted reproductive technology in women free of thyroid disease. Fertil Steril. 2005;83(6):1753–1757.

23.

Kutteh

Yetman

Carr

Beck

Scott

Jr . Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertil Steril. 1999;71(5):843–848.

24.

Baloch

Carayon

Conte-Devolx

. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13(1):3–126.

25.

Surks

Ortiz

Daniels

. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238.

26.

Ghosh

Strahl

Childs

Miller

. Inhibin and estradiol alter gonadotropes differentially in ovine pituitary cultures: changing gonadotrope numbers and calcium responses to gonadotropin-releasing hormone. Endocrinology. 1996;137(11):5144–5154.

27.

Millar

Lowe

Conklin

. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci U S A. 2001;98(17):9636–9641.

28.

Krsmanovic

Martinez-Fuentes

Arora

. Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. Endocrinology. 1999;140(3):1423–1431.

29.

Winkler

Bukulmez

Hardy

Carr

. Gonadotropin releasing hormone antagonists suppress aromatase and anti-Müllerian hormone expression in human granulosa cells. Fertil Steril. 2010;94(5):1832–1839.

30.

Minaretzis

Alper

Oskowith

Lobel

Mortola

Pavlou

. Gonadotropin-releasing hormone antagonist vs agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa–lutein cells. Am J Obstet Gynecol. 1995;172(5):1518–1525.